Addendum: Nasal NK/T cell lymphoma presents with long-term nasal blockage and fever: a rare case report and literature review
Oncotarget. 2023 Dec 1;14:946. doi: 10.18632/oncotarget.28285.NO ABSTRACTPMID:38039411 | PMC:PMC10691816 | DOI:10.18632/oncotarget.28285 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Hai Zou Ke-Hua Pan Liang Wu Hong-Ying Pan Ya-Hui Ding Ming-Hua Zheng Source Type: research
Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin
Oncotarget. 2023 Dec 1;14:949-956. doi: 10.18632/oncotarget.28538.ABSTRACTIn myeloma patients, high levels of soluble BCMA (sBCMA) can limit the efficacy of BCMA-directed therapies. Belantamab-mafodotin is a BCMA antibody-drug conjugate and shows good overall response rates in heavily pretreated patients but progression-free survival data are poor. As the drug induces apoptosis, we hypothesized that sBCMA includes extracellular vesicles (EV) and thus evaluated numbers of BCMA-EV before and during belantamab therapy in 10 myeloma patients. BCMA-EV were significantly higher in patients prior to Belantamab (median: 3227/μl; ...
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Carsten Springer J ürgen Krauter Arne Trummer Source Type: research
Risk factors for long-term arm morbidities following breast cancer treatments: A systematic review
CONCLUSIONS: The main risk factors for long-term morbidity are removal of lymph nodes from the axilla, body mass index >30, having undergone a mastectomy, the stage of the disease, radiation therapy, chemotherapy, infection and trauma to the affected arm after surgery. An understanding of the risk factors for prolonged arm morbidity after surgery can help doctors and therapists in making personalized decisions about the need and timing of rehabilitation treatments.PMID:38039404 | PMC:PMC10691815 | DOI:10.18632/oncotarget.28539 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Ifat Klein Michael Friger Merav Ben David Danit Shahar Source Type: research
Retraction: Matrine alleviates lipopolysaccharide-induced intestinal inflammation and oxidative stress via CCR7 signal
Oncotarget. 2023 Dec 1;14:943. doi: 10.18632/oncotarget.28119.NO ABSTRACTPMID:38039405 | PMC:PMC10691811 | DOI:10.18632/oncotarget.28119 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Guojun Wu Wenhong Zhou Junfeng Zhao Xiaohua Pan Yongjie Sun Hao Xu Peng Shi Chong Geng Ling Gao Xingsong Tian Source Type: research
Therapeutic potentials and challenges of cytostatic persister cancer cells
Oncotarget. 2023 Dec 1;14:944-945. doi: 10.18632/oncotarget.28488.NO ABSTRACTPMID:38039406 | PMC:PMC10691818 | DOI:10.18632/oncotarget.28488 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Paul Y Kim Cheuk T Leung Source Type: research
Osteopontin induces mitochondrial biogenesis in deadherent cancer cells
This study confirms a functional connection between the short-term oxidative metabolism and the longer-term mitochondrial biogenesis in cancer metastasis - both are induced by Osteopontin-c. The results imply possible mechanisms and targets for treating cancer metastasis.PMID:38039408 | PMC:PMC10691814 | DOI:10.18632/oncotarget.28540 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Gulimirerouzi Fnu Georg F Weber Source Type: research
Reductive carboxylation of glutamine as a potential target in acute myeloid leukemia
Oncotarget. 2023 Dec 1;14:947-948. doi: 10.18632/oncotarget.28474.NO ABSTRACTPMID:38039409 | PMC:PMC10691817 | DOI:10.18632/oncotarget.28474 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Alessia Roma Lawrence D Goodridge Paul A Spagnuolo Source Type: research
Addendum: Nasal NK/T cell lymphoma presents with long-term nasal blockage and fever: a rare case report and literature review
Oncotarget. 2023 Dec 1;14:946. doi: 10.18632/oncotarget.28285.NO ABSTRACTPMID:38039411 | PMC:PMC10691816 | DOI:10.18632/oncotarget.28285 (Source: Oncotarget)
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Hai Zou Ke-Hua Pan Liang Wu Hong-Ying Pan Ya-Hui Ding Ming-Hua Zheng Source Type: research
Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin
Oncotarget. 2023 Dec 1;14:949-956. doi: 10.18632/oncotarget.28538.ABSTRACTIn myeloma patients, high levels of soluble BCMA (sBCMA) can limit the efficacy of BCMA-directed therapies. Belantamab-mafodotin is a BCMA antibody-drug conjugate and shows good overall response rates in heavily pretreated patients but progression-free survival data are poor. As the drug induces apoptosis, we hypothesized that sBCMA includes extracellular vesicles (EV) and thus evaluated numbers of BCMA-EV before and during belantamab therapy in 10 myeloma patients. BCMA-EV were significantly higher in patients prior to Belantamab (median: 3227/μl; ...
Source: Oncotarget - December 1, 2023 Category: Cancer & Oncology Authors: Carsten Springer J ürgen Krauter Arne Trummer Source Type: research
The double-edge sword of CRISPR application for < em > in vivo < /em > studies
Oncotarget. 2023 Nov 27;14:919-920. doi: 10.18632/oncotarget.28459.NO ABSTRACTPMID:38010820 | PMC:PMC10681099 | DOI:10.18632/oncotarget.28459 (Source: Oncotarget)
Source: Oncotarget - November 27, 2023 Category: Cancer & Oncology Authors: Martin K Thomsen Source Type: research
The double-edge sword of CRISPR application for < em > in vivo < /em > studies
Oncotarget. 2023 Nov 27;14:919-920. doi: 10.18632/oncotarget.28459.NO ABSTRACTPMID:38010820 | DOI:10.18632/oncotarget.28459 (Source: Oncotarget)
Source: Oncotarget - November 27, 2023 Category: Cancer & Oncology Authors: Martin K Thomsen Source Type: research
FAAH inhibition ameliorates breast cancer in a murine model
In this study, Fatty Acid Amide Hydrolase (FAAH) inhibition and endocannabinoids were examined as therapeutic alternatives. FAAH is an integral membrane enzyme that hydrolyzes endocannabinoids, rendering them inactive, and FAAH inhibition is predicted to increase cancer cell death. To test this, breast cancer cells were probed for FAAH expression using Western blot analysis, treated with FAAH inhibitors, exogenous endocannabinoids, and combinations of the two treatments, and assessed for viability. High levels of FAAH were observed in different breast cancer cell lines. FAAH inhibition was more effective than exogenous end...
Source: Oncotarget - November 3, 2023 Category: Cancer & Oncology Authors: Mallika Tripathy Amy Bui Jared Henderson Jeffrey Sun Christian Rutan Woods Soumya Somani Thao Doan Anto Sam Crosslee Louis Sam Titus Chandra Mohan Source Type: research
The uncharted role of HER2 mutant alleles in breast cancer
Oncotarget. 2023 Oct 31;14:904-907. doi: 10.18632/oncotarget.28489.ABSTRACTSomatic HER2 mutations are a novel class of therapeutic targets across different cancer types. Treatment with the tyrosine kinase inhibitor (TKI) neratinib as a single agent continues to be evaluated in HER2-mutant metastatic disease. However, responses are heterogeneous, with frequent early progression. Herein, we discuss the under-explored effects of individual HER2 mutant alleles on therapeutic response, a role for HER2 mutation in metastatic propensity, and differences in patient outcomes in ER+ invasive lobular carcinoma (ILC) versus invasive d...
Source: Oncotarget - November 3, 2023 Category: Cancer & Oncology Authors: Rashi Kalra Bora Lim Matthew J Ellis Shyam M Kavuri Source Type: research
